A tumor-microenvironment-responsive M1 macrophage-membrane-camouflaged nanoplatform potentiates polyphyllin VII immunotherapy through disrupting the ASNS-mTOR axis and inducing immunogenic cell death for solid tumor treatment.
Abstract
Polyphyllin VII, a steroidal saponin derived from Paris polyphylla, exhibits potent anti-tumor activity across multiple cancer types. Its clinical application is severely hampered by poor water solubility, non-specific biodistribution, and inherent cytotoxicity to normal tissues. Here, we report a rationally engineered biomimetic nanoplatform -M1-PVII·MSN@PDA- that systematically addresses these translational bottlenecks through a tri-functional design: mesoporous silica nanoparticles (MSNs) provide high-capacity drug loading and aqueous dispersibility; a polydopamine (PDA) coating serves as a tumor-microenvironment-responsive molecular gatekeeper, preventing premature drug leakage during systemic circulation while enabling pH/ near-infrared (NIR)-triggered release at tumor sites; and M1 macrophage membrane camouflage confers immune evasion, prolonged circulation, and active tumor homing through inherited surface proteins including CD47 and integrin α4/β1. Comprehensive in vitro and in vivo characterization demonstrates that this nanoparticle achieves a high PVII loading efficiency, suppresses premature drug release in physiological conditions, and selectively releases its payload under tumor-mimicking acidic and oxidative conditions. Mechanistically, released PVII disrupts the asparagine synthetase (ASNS)-mTOR signaling axis, inducing metabolic reprogramming and asparagine depletion in tumor cells, thereby suppressing proliferation and triggering immunogenic cell death (ICD) characterized by calreticulin (CRT) exposure and HMGB1 release. ICD-driven danger signals promote dendritic cell (DC) maturation, facilitate cytotoxic T-lymphocyte infiltration, and reshape the immunosuppressive TME toward an immunostimulatory phenotype. In murine solid tumor models, M1-PVII·MSN@PDA demonstrates superior tumor suppression, enhanced immune activation, and favorable biosafety profiles compared to free PVII. Collectively, this work establishes a mechanistically grounded, multi-functional nanoimmunotherapy strategy that integrates metabolic intervention with innate immune reprogramming, providing a translational framework for next-generation solid tumor treatment.